PFI results show that POLD2 is a risk factor for patients with ACC, BLCA, BRCA, ESCA, HNSC, KICH, KIRC, KIRP, LGG, LIHC, LUAD, MESO, PRAD, SARC, and TGCT, and a protective factor for patients with GBM, PAAD, and READ (Figure 6C). Here, POLD2 is linked to adrenal cortex carcinoma.